Pneumocystis jirovecii pneumonia (PJP) is an opportunistic fungal infection of immunocompromised hosts which causes in significant morbidity and mortality. The current standard of care, trimethoprim-sulfamethoxazole (TMP-SMX) at a dose of 15-20 mg/kg/day of TMP, is associated with serious adverse events, including hypersensitivity reactions, drug-induced liver injury, cytopenia, and renal failure occurring among 20-60% of patients. The frequency of adverse events increases in a dose dependent manner and commonly limits the use of TMP-SMX.
Reduced treatment doses of TMP-SMX for PJP reduced ADEs without mortality differences in a recent meta-analysis of observational studies. We therefore propose a Phase III randomized, placebo-controlled trial to directly compare the efficacy and safety of low dose (10 mg/kg/day of TMP) compared to the standard-of-care (15 mg/kg/day) among patients with PJP for the primary outcome of death, new mechanical ventilation, and change of treatment.

Start Date01 Sep 2024

Sponsor / Collaborator

McGill University Health Center

ChiCTR2400088397 / SuspendedPhase 4IIT

Optimisation of the dosing regimen of trimethoprim/sulfamethoxazole in septic patients on CRRT based on the PPK-PD-PG model

Start Date30 Aug 2024

Sponsor / Collaborator-

NCT06499233 / RecruitingPhase 4IIT

Efficacy and Safety of Prophylactic Treatment for Pneumocystis Jirovecii Pneumonia (PJP) in Patients With Autoimmune Inflammatory Rheumatic Disease (AIIRD)

This is an open-labeled, prospective clinical study aims at collecting and analyzing baseline characteristics of autoimmune inflammatory rheumatic disease (AIIRD) patients receiving sulfanilamide for preventive purposes, as well as subsequent follow-up data, in order to assess the efficacy and safety of the medication. Additionally, through a stratified analysis of risk factors, the investigators aim to identify the AIIRD population that would benefit most from preventive medication based on a favorable benefit-risk ratio.

Start Date20 Jul 2024

Sponsor / Collaborator

Tongji Hospital Tongji Medical College of HUST

100 Clinical Results associated with Sulfamethoxazole/Trimethoprim

100 Translational Medicine associated with Sulfamethoxazole/Trimethoprim

100 Patents (Medical) associated with Sulfamethoxazole/Trimethoprim

10,702

Literatures (Medical) associated with Sulfamethoxazole/Trimethoprim

01 Jan 2025·INTERNATIONAL JOURNAL OF HYGIENE AND ENVIRONMENTAL HEALTH

Prevalence of antibiotic-resistant enterobacteriaceae in domestic wastewater and associated health risks in reuse practices

Article

Author: Abagale, Felix K. ; Cangola, Jenita ; Cobbina, Samuel J ; Osei, Richard A ; Cobbina, Samuel J. ; Abagale, Felix K ; Osei, Richard A.

The use of wastewater for non-potable purposes is an important alternative for addressing water scarcity, especially in developing regions. However, minimizing the risks, particularly those associated with emerging contaminants that may induce resistance among pathogens in wastewater, is crucial. This study assessed the occurrence of antibiotic-resistant bacteria in untreated wastewater used for agricultural purposes and evaluated the quantifiable health risks associated with this practice in Tamale, Ghana. The resistance of some Enterobacteriaceae, such as E. coli, Klebsiella, and Salmonella-Shigella, to four commonly used antibiotics in Ghana was assessed using a conventional microbiological culture approach and the Kirby Bauer disk diffusion method. A Quantitative Microbial Risk Assessment (QMRA) was performed to estimate the health risks associated with two distinct scenarios of wastewater reuse: (1) accidental ingestion of contaminated wastewater and soil, and (2) consumption of vegetables irrigated with wastewater. This approach applied a Monte Carlo simulation based on 10,000 interactions and identified E. coli O157:H7 as the reference pathogen. Among Enterobacteriaceae, Klebsiella pneumoniae, Salmonella-Shigella and E. coli were isolated, in concentrations exceeding the limit recommended by the World Health Organization (10³ CFU/100 ml). All the isolated bacteria were resistant to metronidazole (5 μg). Thirty-three per cent of Klebsiella pneumoniae isolates were intermediate/moderately susceptible, and all other bacteria were resistant to amoxicillin (30 μg). All Klebsiella pneumoniae and the majority of Salmonella-Shigella (69.8 %) isolates were resistant to trimethoprim-sulfamethoxazole (25 μg) and tetracycline (30 μg). When assessing health risks, the mean annual probability of infection associated with consuming vegetables irrigated with wastewater varied between 5.14 × 10^-2 and 9.79 × 10^-1 per person per year. Conversely, for the accidental ingestion scenario, the probability was 1.00 per person per year. In these scenarios, the probability of illness ranged from 1.29 × 10^-2 to 2.4 × 10^-1 and 2.5 × 10^-1 per person per year. The health risks posed by these findings surpass the maximum threshold prescribed by the World Health Organization, thereby emphasizing the need for prompt mitigation strategies.

31 Dec 2024·Gut microbes

The effects of antibiotic exposures on the gut resistome during hematopoietic cell transplantation in children

Article

Author: Arshad, Mehreen ; Jenkins, Kirsten ; Ward, Doyle V ; Bucci, Vanni ; Martin, Paul L ; Bhattarai, Shakti K ; Seed, Patrick C ; Chao, Nelson J ; Heston, Sarah M. ; Heston, Sarah M ; Kelly, Matthew S ; Young, Rebecca R ; Stokhuyzen, Andre

Antibiotic resistance is a global threat driven primarily by antibiotic use. We evaluated the effects of antibiotic exposures on the gut microbiomes and resistomes of children at high risk of colonization by antibiotic-resistant bacteria. We performed shotgun metagenomic sequencing of 691 serially collected fecal samples from 80 children (<18 years) undergoing hematopoietic cell transplantation. We evaluated the effects of aerobic (cefepime, vancomycin, fluoroquinolones, aminoglycosides, macrolides, and trimethoprim-sulfamethoxazole) and anaerobic (piperacillin-tazobactam, carbapenems, metronidazole, and clindamycin) antibiotic exposures on the diversity and composition of the gut microbiome and resistome. We identified 372 unique antibiotic resistance genes (ARGs); the most frequent ARGs identified encode resistance to tetracyclines (n = 88), beta-lactams (n = 84), and fluoroquinolones (n = 79). Both aerobic and anaerobic antibiotic exposures were associated with a decrease in the number of bacterial species (aerobic, β = 0.71, 95% CI: 0.64, 0.79; anaerobic, β = 0.66, 95% CI: 0.53, 0.82) and the number of unique ARGs (aerobic, β = 0.81, 95% CI: 0.74, 0.90; anaerobic, β = 0.73, 95% CI: 0.61, 0.88) within the gut metagenome. However, only antibiotic regimens that included anaerobic activity were associated with an increase in acquisition of new ARGs (anaerobic, β = 1.50; 95% CI: 1.12, 2.01) and an increase in the relative abundance of ARGs in the gut resistome (anaerobic, β = 1.62; 95% CI: 1.15, 2.27). Specific antibiotic exposures were associated with distinct changes in the number and abundance of ARGs for individual antibiotic classes. Our findings detail the impact of antibiotics on the gut microbiome and resistome and demonstrate that anaerobic antibiotics are particularly likely to promote acquisition and expansion of antibiotic-resistant bacteria.

01 Dec 2024·American journal of ophthalmology case reports

Bacillus coagulans-associated severe necrotizing scleral infection

Article

Author: Fuller, Spencer D ; Doan, Thuy ; Sylvester, Beau ; Certain, Laura ; Shakoor, Akbar

Purpose:

We describe a case of severe scleritis possibly caused by Bacillus coagulans.

Observations:

Conventional laboratory evaluation was inconclusive. The associated organism was identified with metagenomic RNA deep sequencing (MDS). The infection resolved with trimethoprim-sulfamethoxazole treatment.

Conclusions:

This case demonstrates the utility of unbiased, high-throughput sequencing for infectious scleritis.

News (Medical) associated with Sulfamethoxazole/Trimethoprim

12 Aug 2024

·www.globenewswire.com

Locus Biosciences Announces Positive Results from Part 1 of ELIMINATE Phase 2 Trial of the Engineered Bacteriophage Therapy LBP-EC01 Published in The Lancet Infectious Diseases

Primary and secondary objectives were met in the open-label randomized Part 1 of the clinical trial to treat uncomplicated UTIs caused by antibiotic-resistant E. coli Dosing has begun in Part 2, the controlled, double-blind portion of the trial triggered by the success in Part 1 Data support potential of Locus’ engineered bacteriophage platform in combatting the global health crisis of infections caused by multidrug-resistant (MDR) pathogens RESEARCH TRIANGLE PARK, N.C., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Locus Biosciences, Inc. (“Locus”), a clinical-stage biotechnology company developing a new class of precision engineered bacteriophage treatments for a diverse set of bacterial diseases, today announced positive results from Part 1 of its two-part Phase 2 ELIMINATE trial. This Phase 2 trial is evaluating LBP-EC01, a CRISPR-Cas3 genetically engineered bacteriophage therapy designed to treat patients with uncomplicated urinary tract infections (uUTIs) caused by antimicrobial-resistant (AMR) and multi-drug-resistant (MDR) Escherichia coli (E. coli). Data from the randomized, uncontrolled, open-label Part 1 portion of the trial were published in The Lancet Infectious Diseases. Locus also announced that dosing has begun in the randomized, controlled, and blinded Part 2 portion of this Phase 2 study. This clinical trial is supported by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response within the U.S. Department of Health and Human Services. Worldwide, an estimated 150 million people are affected by UTIs each year. Approximately 80% of these are caused by E. coli, often including difficult-to-treat strains that are resistant to commonly used antibiotics. Up to 40% of UTI patients experience a recurrence, often within months of the first episode. Both the U.S. Centers for Disease Control and Prevention and the World Health Organization have identified antibiotic-resistant E. coli as an urgent and serious public health threat requiring the development of new treatments. Part 1 of ELIMINATE enrolled 39 adult female patients, across six United States-based clinical centers and had an overall objective of defining a dosing regimen of LBP-EC01 and oral trimethoprim/sulfamethoxazole (TMP/SMX) to advance to Part 2 of the trial. This overall objective was supported by analysis of the primary outcome of pharmacokinetics (PK) in urine and blood, and the secondary outcome of safety, which were assessed on randomized patients dosed at least once with LBP-EC01. In addition, an exploratory outcome of pharmacodynamic (PD) assessments was performed on 16 evaluable patients. “The need for new targeted antibacterial therapies is urgent given the increasing impact of antibiotic-resistant pathogens, which we see in our clinic every day,” said Juvenal E. Martinez, M.D., an investigator in the trial. “As the first Phase 2 engineered bacteriophage trial, ELIMINATE is breaking new ground in the quest to address increasingly prevalent serious MDR infections. This encouraging initial data support the possible utility of bacteriophages and the potential of LBP-EC01 as a therapeutic option to address drug-resistant bacterial infections, such as UTIs, which have a high recurrence rate due to MDR pathogens.” ELIMINATE Trial Part 1 Results The primary and secondary outcomes of Part 1 were met, and a dosing regimen was identified that was well-tolerated and which led to high drug exposure at the site of infection. No serious adverse events were observed in Part 1, and exposure to LBP-EC01 did not lead to any observations of genetic resistance in any subsequently recovered E. coli samples. Part 1 was initiated with three treatment groups focused on intravenous (IV) delivery of a high 1×1011 plaque forming units (PFU)/dose of LBP-EC01 which was halted after three patients discontinued dosing due to non-serious adverse events of mild tachycardia and afebrile chills. Three updated treatment groups, which focused on a short, 3-day course of intra-urethral (i.e., IU or direct to bladder) and lower exposure IV dosing, replaced the original treatment groups. With this updated dosing approach, a rapid reduction of E. coli in urine was observed four hours after the first treatment which was maintained to the day 10 test of cure (TOC) evaluation. All (16 of 16) patients in the evaluable population had complete resolution of UTI symptoms and 14 of 16 (87.5%) patients demonstrated microbiologic cure or reduction of their bacterial infection below 1×103 colony forming units (CFU)/mL in urine by the day 10 TOC. A dosing regimen of LBP-EC01 given for 2 days IU (2×1012 PFU/dose) and given concurrently for 3 days IV (1×1010 PFU/dose) with concomitant oral TMP/SMX (160 mg TMP/800 mg SMX twice daily) has been advanced into Part 2. ELIMINATE Trial Part 2 underway Part 2 of the ELIMINATE trial has been initiated with patient dosing underway. This randomized, controlled, double-blind portion of the trial will evaluate the efficacy, safety, tolerability, and pharmacokinetics of LBP-EC01 with TMP/SMX. Up to 288 female uncomplicated UTI patients will be enrolled and randomized in a 1:1 ratio where patients will receive LBP-EC01 or placebo for the 3-day dosing regimen selected from Part 1. The primary objective will be to evaluate the effect of LBP-EC01 given with TMP/SMX on its ability to treat acute UTIs in patients with a history of UTI recurrence. The impact of the treatment on reducing UTI recurrence and/or extending the duration of time to the next UTI recurrence will be examined as an exploratory endpoint in a 6-month follow-up evaluation. This trial is registered with ClinicalTrials.gov, NCT05488340, and is ongoing. “These milestones represent a huge step forward in the critical fight against MDR. Over the past eight years, we have invested significant resources to build the Locus engineered bacteriophage platform. We developed our high-throughput robotics and AI technology to optimize a fixed set of precisely engineered phages that target over 95 percent of current uropathogenic E. coli strains, including MDR strains. We also built a world-class viral vector manufacturing facility that produces GMP materials at potency and purity levels higher than any others we have seen in the field to date. These Part 1 data validate our platform and support the advancement of a potential first-in-class therapy,” said Paul Garofolo, Co-founder and CEO of Locus. “We are grateful for the participating sites, clinicians, and patients, and our funding partner BARDA. We are eager to build on this positive momentum as we continue Part 2 of the ELIMINATE trial.” For more information on Part 1 of the ELIMINATE trial, visit clinicaltrials.gov using the identifier NCT05488340. Patients interested in participating in Part 2 can visit www.eliminateuti.com. About LBP-EC01LBP-EC01 is a CRISPR-enhanced bacteriophage therapy in development for the treatment of urinary tract infections and other infections caused by the pathogen E. coli. It is a bacteriophage cocktail engineered with a CRISPR-Cas3 construct targeting the E. coli genome. The precision medicine product works through a unique dual mechanism of action utilizing both the natural lytic activity of the bacteriophage along with the DNA-targeting activity of CRISPR-Cas3. LBP-EC01 previously met all primary and secondary endpoints and demonstrated safety and tolerability in a Phase 1b trial. LBP-EC01 is currently being evaluated in a Phase 2 trial for the treatment of UTIs caused by E. coli. In 2020, Locus and BARDA, part of the Administration for Strategic Preparedness and Response (ASPR) at the U.S. Department of Health and Human Services (HHS), announced an agreement to co-fund development of LBP-EC01. Under the partnership agreement, contract number 75A50120C00169, BARDA will provide up to $93 million to Locus as part of a $152 million program to support Phase 2 and Phase 3 clinical trials and other activities required to seek marketing approval from the U.S. Food and Drug Administration (FDA) for LBP-EC01. About Locus BiosciencesLocus Biosciences is creating a new class of precision biotherapeutics with clinical-stage engineered bacteriophage treatments for a diverse set of bacterial and microbiome/inflammatory diseases. A world-leading bacteriophage discovery, synthetic biology, and manufacturing platform powers the company. Locus engineers bacteriophage - naturally occurring viruses that target bacteria - to kill pathogenic bacteria, while sparing good bacteria, through programmable precision anti-bacterials with CRISPR-Cas3 and other therapeutic payloads. Its artificial intelligence and machine-learning based discovery engine targets bacteria that are associated with disease across multiple therapeutic areas including infectious disease, immunology, and oncology. Locus has secured multiple non-dilutive partnerships to support development of the company’s platform and programs. These include anti-bacterial partnerships with Biomedical Advanced Research and Development Authority (BARDA) for its lead asset targeting E. coli and Combatting Antibiotic Resistant Bacteria Accelerator (CARB-X) for its asset targeting K. pneumoniae. For more on the Research Triangle Park, N.C.-based company, visit www.locus-bio.com. Media Contact:Gina Mangiaracina6 Degrees gmangiaracina@6degreespr.com

Clinical ResultPhase 2License out/inPhase 1

22 May 2024

·www.prnewswire.com

Analysis Group Researchers Develop a Novel Framework to Help Clinicians Predict the Likelihood of Antibiotic-Resistant Bacteria in Patients with Uncomplicated Urinary Tract Infections

BOSTON, May 22, 2024 /PRNewswire/ -- Researchers from Analysis Group, a global leader in health economics and outcomes research (HEOR), have coauthored a study detailing a novel framework that clinicians can use to inform antibiotic prescribing for patients with E. coli-caused uncomplicated urinary tract infections (uUTIs), the most common outpatient infection in the US. The study, published in the journal Clinical Infectious Diseases, is the first to use predictive modeling to categorize patient risk profiles for antimicrobial resistance (AMR) as low, moderate, and high risk across four commonly prescribed antibiotic classes for uUTI. Despite guideline recommendations from the Infectious Diseases Society of America (IDSA) on appropriate first-line antibiotic agents for the treatment of uUTI, 86% of patients are prescribed antibiotic agents that are not considered first-line therapies. These inappropriate prescribing practices contribute to the growth of AMR, treatment failure, persistent uUTI symptoms, adverse patient health outcomes, and increased health care costs. This study was conducted to help provide clinicians with more reliable and efficient approaches for supporting patients with uUTI. Using electronic health record data from 87,487 patients with confirmed E. coli-related uUTI in the US, study investigators developed and validated predictive models to estimate probabilities of E. coli AMR to four commonly prescribed classes of antibiotics for uUTIs (nitrofurantoin, trimethoprim-sulfamethoxazole, β-lactams, and fluoroquinolones). The models identified key predictors of AMR and were used to create a novel risk categorization framework for contextualizing patients' risk for AMR. The predictive models were found to outperform those in existing literature, and the risk categorization framework provided strong separation of risk between patients with truly resistant and truly not resistant E-coli isolates. The study, "Development of Predictive Models to Inform a Novel Risk Categorization Framework for Antibiotic Resistance in E. coli-Causing Uncomplicated Urinary Tract Infection," was published in April by Clinical Infectious Diseases. Investigators included Analysis Group Managing Principals Lisa Pinheiro and Jimmy Royer, Managers Kalé Kponee-Shovein and Chi Gao, Associate Malena Mahendran, and Senior Research Professional Fernando Kuwer; Ryan K. Shields of the University of Pittsburgh; Richard Colgan of the University of Maryland School of Medicine; and Ashish V. Joshi, Fanny S. Mitrani-Gold, Patrick Schwab, Diogo Ferrinho, Madison T. Preib, and Jennifer Han of GSK. Funding for this study was provided by GSK. To learn more about Analysis Group's HEOR capabilities, visit About Analysis Group's HEOR, Epidemiology & Market Access Practice Founded in 1981, Analysis Group is one of the largest international economics consulting firms, with more than 1,200 professionals across 14 offices. Analysis Group's health care experts apply analytical expertise to health economics and outcomes research (HEOR), clinical research, market access and commercial strategy, and health care policy engagements, as well as drug safety-related engagements in epidemiology. Analysis Group's internal experts, together with our network of affiliated experts from academia, industry, and government, provide our clients with exceptional breadth and depth of expertise and end-to-end consulting services globally. Contact: Analysis Group Eric Seymour, +1 978 273 6049 [email protected] SOURCE Analysis Group

25 Apr 2024

·www.fiercepharma.com

Utility Therapeutics wins FDA nod for UTI antibiotic that has been on the market in Europe for 40-plus years

Nearly half of women will get a urinary tract infection in their lifetime. For the first time in more than 20 years the FDA has approved an antibiotic to treat the condition. For the first time in more than 20 years, the FDA has approved a treatment for uncomplicated urinary tract infections (uUTI). And the nod has come for an oral antibiotic that has been available in Europe for more than 40 years. It’s an odd set of circumstances and a dose of foresight by Utility Therapeutics that bring Pivya (pivmecillinam) to the market in the United States in the therapy’s golden years. The London-based company was formed specifically to develop and commercialize pivmecillinam in the U.S. where antimicrobial resistance is growing to standard of care antibiotics. The decreased “utility” of first-line antibiotics and the void the company is attempting to fill in the U.S. were the inspiration of the name of the company. And the void is significant as more than 30 million uUTIs are diagnosed every year in the U.S., with nearly half of all women contracting the infection at some point in their life. Outside of hospital setting, UTIs account for more antibiotic use than any other disorder. In 2018, Utility inked a licensing agreement with LEO Pharma, acquiring the U.S. rights to pivmecillinam and its subcutaneous formulation mecillinam, which the company has submitted for approval as a first-line therapy for complicated urinary tract infections (cUTI) in the hospital setting. The difference between cUTIs and uUTIs is that the former has reached the kidneys while the latter is limited to the bladder. “The FDA is committed to fostering new antibiotic availability when they prove to be safe and effective and Pivya will provide an additional treatment option for uncomplicated UTIs,” Peter Kim, M.D., the director of the Division of Anti-Infectives at the FDA’s Center for Drug Evaluation and Research, said in a release. The year that Utility acquired the rights to pivmecillinam and mecillinam, the FDA signed off on each as a Qualified Infectious Disease Product (QIDP). The status is extended to antibacterial and antifungal drug candidates intended to treat serious or life-threatening infections. When a QIDP treatment is approved, it gains an additional five years of market exclusivity. On the same day in January, when Utility revealed that the FDA had accepted the company’s new drug applications for pivmecillinam and mecillinam, it also announced it had received private funding from the AMR Action Fund. The global initiative—which was established by several prominent drugmakers including Amgen, Bayer, Eli Lilly, GSK, Novo Nordisk and Roche—invests in the development of new antimicrobial therapeutics. In addition to being a prodrug, which means that it is not pharmacologically active until it is digested and absorbed into the system, Pivya has a unique mechanism of action, targeting penicillin binding protein-2 in the cell wall of gram-negative bacteria. Pivya’s efficacy was assessed in separate trials versus placebo, an oral antibacterial and ibuprofen. The primary measure of efficacy in the studies was the composite response rate, which included clinical cure (resolution of the symptoms of the uUTI that were present in patients at trial entry and no new symptoms) and microbiological response (demonstration that the bacteria cultured from patients’ urine at trial entry was reduced). In the placebo trial, 62% of the participants who received Pivya achieved composite response compared to 10% of those on placebo. In the oral antibacterial trial, 72% of the subjects who received Pivya achieved composite response versus 76% of those on the comparator. In the third trial, 66% of the subjects who received Pivya achieved composite response compared to 22% of those on ibuprofen. Commonly prescribed drugs for uUTIs in the U.S. are bactrim (sulphamethoxazole/trimethoprim), nitrofuranatoin and fluoroquinolones. But more than 1 in 5 who receive these are resistant, which can lead to progression of the disease, including life-threatening sepsis. Last month, Germany’s Allecra Therapeutics scored FDA approval for its antibiotic Exblifep, which is a combination of cephalosporin antibacterial cefepime and the beta-lactamase inhibitor enmetazobactam, to treat cUTI. The approval came days after the U.S. regulator rejected another combo therapy in the same indication from Venatorx Pharmaceuticals and Melinta Therapeutics.

License out/inDrug ApprovalClinical Result

100 Deals associated with Sulfamethoxazole/Trimethoprim

External Link

KEGG	Wiki	ATC	Drug Bank
-	Sulfamethoxazole/Trimethoprim	J01EE01	-

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Infectious Diseases	US	Pharmaceutical Associates, Inc.	07 Jan 1983
Enteritis	JP	Tsuruhara Pharmaceutical Co. Ltd.	24 Mar 1981
Bacterial Infections	CN	Tianjin Lisheng Pharmaceutical Co., Ltd.	01 Jan 1981
Cystitis	JP	Shionogi Pharma Co., Ltd.	14 Feb 1976
Cystitis	JP	Taiyo Pharma Co., Ltd.	14 Feb 1976
Infectious enteritis	JP	Shionogi Pharma Co., Ltd.	14 Feb 1976
Infectious enteritis	JP	Taiyo Pharma Co., Ltd.	14 Feb 1976
Paratyphoid Fever	JP	Shionogi Pharma Co., Ltd.	14 Feb 1976
Pyelonephritis	JP	Taiyo Pharma Co., Ltd.	14 Feb 1976
Pyelonephritis	JP	Shionogi Pharma Co., Ltd.	14 Feb 1976
Secondary infection	JP	Shionogi Pharma Co., Ltd.	14 Feb 1976
Typhoid Fever	JP	Taiyo Pharma Co., Ltd.	14 Feb 1976
Typhoid Fever	JP	Shionogi Pharma Co., Ltd.	14 Feb 1976
Acute otitis media	US	Sun Pharmaceutical Industries, Inc.	30 Jul 1973
Acute otitis media	US	Monarch Pharmaceuticals LLC	30 Jul 1973
Bronchitis, Chronic	US	Sun Pharmaceutical Industries, Inc.	30 Jul 1973
Bronchitis, Chronic	US	Monarch Pharmaceuticals LLC	30 Jul 1973
Dysentery, Bacillary	US	Sun Pharmaceutical Industries, Inc.	30 Jul 1973
Dysentery, Bacillary	US	Monarch Pharmaceuticals LLC	30 Jul 1973
Pneumonia, Pneumocystis	US	Monarch Pharmaceuticals LLC	30 Jul 1973

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Malaria	Phase 3	CF	Institut Pasteur	01 Dec 2013

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05418777 (CTgov)	Phase 1/2	Pulmonary Disease, Chronic Obstructive	1	Trimethoprim Sulfamethoxazole (TMP-SMX)	jzdoyiuibv(cfhfpajpxi) = eywgmtkcdt dhiqdxoyux (czcyvhtuxc, rdlahyrlwx - hnxqbpntcb) View more	-	29 Nov 2023
				Placebo (Placebo)	zhmsbckjdv(vcxwlttqcd) = hrviivhtbe beymikhvxu (uktvubmqcp, nmpajkewgs - gjnkradzfn) View more
Tandem Meetings ASTCT and CIBMTR2023	Not Applicable	Hematopoietic stem cell transplantation	-	Trimethoprim/Sulfamethoxazole (TMP-SMX)	hlajxnaory(nkxiimxeuw) = vakzqvpagq vobdwhktye (dkzpndfdmq ) View more	-	01 Feb 2023
				Other medications	hlajxnaory(nkxiimxeuw) = icbsxznazr vobdwhktye (dkzpndfdmq ) View more
ASN2022	Not Applicable	-	-	Bactrim	gnmgizzfvx(payszgubty) = treulpprww edcltikanb (yzgjoytgtc ) View more	-	05 Nov 2022
EULAR2022	Not Applicable	Rheumatic Diseases	438	Patients with AEs of SMX/TMP	gqhcucgexm(jlcninrqfz) = hhxjuhqgxu eomfcqyedp (ufglncpvbv ) View more	Positive	01 Jun 2022
				Patients without AEs of SMX/TMP	gqhcucgexm(jlcninrqfz) = zpozewjvbs eomfcqyedp (ufglncpvbv ) View more
NCT03431168 (PREMISE, CTgov)	Phase 2	Malaria \| HIV Infections	308	TMPS+Azithromycin (Azithromycin/TMPS)	dszdvzdljo(szfexcvucn) = zvqeikewux rlwrywnyjp (psydrjfjlc, qlcspwejih - kvnzmvaukn) View more	-	04 May 2022
				Placebo/TMPS (Placebo/TMPS)	dszdvzdljo(szfexcvucn) = xvidjmtmjg rlwrywnyjp (psydrjfjlc, yssdnerehz - bfabpgpizu) View more
ASN2021	Not Applicable	Gout \| Hyperuricemia	-	Trimethoprim/Sulfamethoxazole (TMP/SMX)	bjhyfaynaf(aqohaldfql) = btxlngbsug inothjiadg (qcxwftbyis ) View more	-	27 Oct 2021
Pubmed \| Clin Infect Dis	Not Applicable	-	1,499	Continue daily co-trimoxazole	xrxmwausfw(oqaobxyhao) = hfgoifdknl eruxbdlicq (sugefkdtvj )	-	21 Mar 2021
				Discontinue daily co-trimoxazole and begin weekly chloroquine	xrxmwausfw(oqaobxyhao) = xwczsgbslt eruxbdlicq (sugefkdtvj )
NCT02759120 (CleanUp-IPF, CTgov)	Phase 3	Idiopathic Pulmonary Fibrosis	513	No Intervention: Standard of Care	scectkprzx(fivipizaig) = eguuguwduc bcnutcgivq (ripdiaqral, jhapgpmsma - liykfcybvu) View more	-	03 Mar 2021
NCT00867789 (CTgov)	Not Applicable	Abscess	140	Trimethoprim-sulfamethoxazole (Trimethoprim-sulfamethaxazole)	bhlmlnbxwu(vlvtpqwqhg) = mgofcczbat cdufyyqfjd (jozocjcmji, huvbvnbdwh - tkbvtxkytp) View more	-	26 Jan 2021
				sugar pill (Sugar Pill)	bhlmlnbxwu(vlvtpqwqhg) = jjnszujeds cdufyyqfjd (jozocjcmji, pjmznukbxo - xwmhjiekhm) View more
ACR2020	Not Applicable	Systemic Lupus Erythematosus	-	Trimethoprim-sulfamethoxazole	dhghzlkohw(zoqkmijvcl) = velzrpfuus ervlrxjpja (slewseieae )	-	09 Nov 2020
				Trimethoprim-sulfamethoxazole	dhghzlkohw(zoqkmijvcl) = owrjorzyws ervlrxjpja (slewseieae )

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis